Kevin Caldwell
Vascular Surgery · Lewes, DENPI 1881986909
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (55.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Angiodynamics, Inc. accounts for 63.5% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $13,257, 5.2 times the $2,544 reported in 2019.
Across 235 payments — averaging $169.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$25K
- Medtronic$7K
- Silk Road Medical, Inc.$2K
- Boston Scientific$2K
- W. L. Gore & Associates, Inc.$1K
- Cardiovascular Systems Inc.$790
- plus $3K from 29 others
What the payments were for
- Travel & lodging$4,72712%
- Food & beverage$9,92225%
- Education$3,2008%
- Other$21,94455%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 7 | $25,269 |
| Medtronic(2 entities) | 61 | $6,636 |
| Silk Road Medical, Inc. | 35 | $1,811 |
| Boston Scientific | 27 | $1,579 |
| W. L. Gore & Associates, Inc. | 15 | $1,022 |
| Cardiovascular Systems Inc. | 11 | $790 |
| Cook Medical LLC | 9 | $534 |
| Johnson & Johnson(2 entities) | 25 | $408 |
| Bard Peripheral Vascular, Inc. | 4 | $236 |
| Bolton Medical Inc | 5 | $236 |
| Shape Memory Medical Inc. | 1 | $150 |
| Penumbra, Inc. | 1 | $130 |
| Endologix LLC | 2 | $114 |
| Edwards Lifesciences | 1 | $82 |
| Smith+Nephew | 4 | $80 |
| Inari Medical, Inc. | 2 | $73 |
| Philips North America LLC | 1 | $71 |
| Artivion, Inc. | 1 | $61 |
| Osiris Therapeutics Inc. | 1 | $59 |
| Terumo Medical Corporation | 2 | $53 |
| Stryker | 1 | $52 |
| Amgen | 2 | $38 |
| Abbott | 2 | $37 |
| Baxter Healthcare | 2 | $36 |
| KCI USA, Inc. | 2 | $30 |
| Lemaitre Vascular, Inc. | 2 | $28 |
| Elutia, Inc. | 1 | $26 |
| BD | 1 | $26 |
| Tactile Systems Technology Inc | 1 | $24 |
| Heartflow, Inc. | 1 | $24 |
| Medela LLC | 1 | $22 |
| Kerecis Limited | 1 | $19 |
| Covidien LP | 1 | $18 |
| Sanara Medtech Inc. | 1 | $15 |
| Nuwellis, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$21,944
- Valiant Captivia$3,343
- EVLT$1,600
- VenaCure 1470 Pro$1,600
- ENROUTE Transcarotid Neuroprotection System$1,420
- ENROUTE Transcarotid Stent System$786
- ENHANCE Transcarotid Peripheral Access Kit$786
- ENROUTE 0.014 Guidewire$786
- NA$627
- ENDURANT IIS$576
- Endurant$576
- GENERAL ANGIOGRAPHY$440
- Diamondback Peripheral$245
- ENROUTE Transcarotid Stent$234
- GORE VIABAHN VBX Balloon Expandable Endo$172
- TREO ABDOMINAL STENT-GRAFT SYSTEM$150
- IMPEDE EMBOLIZATION PLUG$150
- TAG Thoracic Endoprosthesis$139
- Varithena Administration Pack$134
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$132
How this compares
Too few vascular surgery providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 20 | $19,745 |
| EliquisApixaban | 11 | $8,454 |
| ClopidogrelClopidogrel Bisulfate | 44 | $623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $408 | $19,74520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular surgery providers in Delawareon file to place this against a meaningful peer group, so we don't.
Other vascular surgery in Lewes
- Carlos NevesLewes$52K
- Sean RyanLewes$47K
- Mayer KatzLewes$75
- Reid RavinNewark$17K
- Luiz AraujoDover$10K
- Mikael FadoulNewark$7K
- Kathryn BowserNewark$5K
- Devaguptapu RaoNewark$4K
- Thomas EvansNewark$4K
- Frederic HaradNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.